“By charging $94,500 for Harvoni, Gilead has made clear that it values Wall Street above the interests of patients, taxpayers, employers, and working families who must shoulder the burden of high health care costs. The company’s refusal to take a more reasonable and moderate approach to pricing cements its status as the poster child for everything that is wrong with pharmaceutical industry pricing.
Gilead’s escalator pricing could undermine the system of health care finance that has supported the biomedical innovation that we all want to continue. Unreasonable pricing not based on value threatens the sustainability of our entire health care system.”
Read John Rother’s blog post.
Read John Rother’s letter to lawmakers urging them to consider value transparency for pharmaceuticals.
See full press release: http://www.nchc.org/gilead-rejects-reasonable-approach-with-94500-new-hepatitis-c-drug